- Home
- » Tags
- » Roflumilast
Top View
- Respiratory: Bronchodilators for COPD
- Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
- Simvastatin Up-Regulates Adenosine Deaminase and Suppresses
- Bifunctional Drugs for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- Q3 2017,ERX.NPA.37 Roflumilast (Daliresp)
- Anti‑Inflammatory Effect of Ciclamilast in an Allergic Model Involving the Expression of PDE4B
- Roflumilast: a New Oral, Once-Daily Therapy for COPD Editor By: Mallary Wood, Pharm.D
- Roflumilast (Daliresp®) EOCCO POLICY
- Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.20 Line of Business: Medicaid Revision Log
- Inhaled Beta-Agonist Combination Agents
- Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke–Exposed Mice
- (12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
- Chronic Obstructive Pulmonary Disease (“COPD”) Medication Guide
- Drug Development for Asthma and COPD: a Regulatory Perspective
- Roflumilast Versus Theophylline for COPD
- Effect of Roflumilast on Exacerbations in Patients with Severe Chronic
- Justification
- Phosphodiesterase 4 Inhibition Reduces Lung Fibrosis Following Targeted Type II Alveolar Epithelial Cell Injury
- ROFLEX™: a NOVEL FORMULATION for TREATMENT of RESPIRATORY and ANXIETY DISORDERS Pondera Biotechnologies, Inc. CLINICAL NEEDS
- GOLD 2020 Revision the Basic Principles Remain the Same
- 2020 Pocket Guide
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- POCKET GUIDE to COPD DIAGNOSIS, MANAGEMENT, and PREVENTION a Guide for Health Care Professionals 2019 REPORT GLOBAL INITIATIVE for CHRONIC OBSTRUCTIVE LUNG DISEASE
- Roles of Roflumilast, a Selective Phosphodiesterase 4 Inhibitor, in Airway Diseases
- CDR Clinical Review Report for Trelegy Ellipta
- 207930Orig1s000
- Customs Tariff - Schedule Xxi - 1
- Roflumilast (Daliresp) for Chronic Obstructive Pulmonary Disease ORALIA V
- Methods Coronavirus Disease 2019 (COVID-19)
- Literature Search Strategy for Treatment of Stable
- Topic: New Treatment = Better Outcome?
- Diprophylline Inhibits Non‑Small Cell Lung Cancer A549 Cell Proliferation and Migration, and Promotes Apoptosis, by Downregulating PI3K Signaling Pathway
- DALIRESP in Patients DALIRESP Safely and Effectively
- Therapeutic and Toxic Blood Concentrations of More Than 1100 Drugs and Other Xenobiotics
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Clinicaltrials.Gov Search Results 08/31/2021
- Matera Doxofylline Is Not 2017
- Roflumilast: a Novel Phosphodiesterase 4 Inhibitor for the Treatment of Inflammatory Airways Disease
- THE ROLE of Nitric Oxide in GLAUCOMA
- Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Infl
- For Peer Review Only Journal: BMJ Open
- Elevated Cyclic AMP and PDE4 Inhibition Induce Chemokine Expression in Human Monocyte-Derived Macrophages
- Bifunctional Drugs for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Trelegy Ellipta, INN-Fluticasone Furoate / Umeclidinium / Vilanterol
- Respiratory Beta-Agonist Combination Agents
- Harmonized Tariff Schedule of the United States (2006) (Rev
- The PDE4 Inhibitor Roflumilast Reduces Sputum Neutrophil and Eosinophil
- Ethynylindole Compounds Ethynylindolverbindungen Composés D’Éthynylindole
- Harmonized Tariff Schedule of the United States (2003) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.20 Line of Business: Medicaid Revision Log
- 022522Orig1s000
- Commissioning Support Glycopyrronium Bromide ®▼ (Seebri Breezhaler )
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases
- Update on Roflumilast, a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease
- UPDATE in CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD